Home
News
Create
Screeners
Insights
Aptus Pharma
330.
20
+15.70
(+4.99%)
Market Cap
₹226.57 Cr
PE Ratio
-
Industry
Consumer Goods
Buy
Sell
Company Performance:
1D
+4.99%
1M
+39.35%
6M
+289.20%
1Y
+289.20%
5Y
+289.20%
View Company Insights
Latest news about Aptus Pharma
Aptus Pharma Limited Expands into Life-Saving Injectables and ICU Care Segment
Feb 26, 2026
Aptus Pharma Limited has announced its expansion into the Life-Saving Injectables and ICU Care product category through a regulatory filing dated February 26, 2026. The new portfolio will focus on products for severe infections, sepsis, and critical care conditions administered in hospital settings. This strategic move follows the company's recent entry into OTC and Uro Care segments and aligns with its growth strategy to strengthen presence across prescription, institutional, and retail healthcare segments.
Aptus Pharma Limited Receives 'Fastest Growing Ethical Pharma Company' Award from News 18 Group
Feb 24, 2026
Aptus Pharma Limited Releases Comprehensive Investor Presentation Under SEBI Regulations
Feb 07, 2026
Apple faces $38 billion fine risk as CCI defends global turnover-based penalty law in antitrust case
Jan 09, 2026
Apple iPhone 17e Launch Timeline Confirmed: February 2026 Release Expected
Jan 08, 2026
More news about Aptus Pharma
07
Jan 26
Apple iPhones to Get 200MP Camera by 2028, Says Morgan Stanley Report
Morgan Stanley forecasts Apple will introduce Samsung-supplied 200MP cameras in iPhone 21 Pro models by 2028, extending beyond earlier iPhone 18 predictions. The timeline allows supply chain diversification beyond Sony and potential U.S. production at Samsung's Austin facility. Apple is also exploring STMicroelectronics for LiDAR supply, with under-display Face ID expected in 2027 for the iPhone's 20th anniversary.
31
Dec 25
Apple's Restrained AI Strategy Set To Pay Dividends In 2026: Report
Apple's measured AI investment strategy contrasts sharply with aggressive competitor spending, allowing the company to maintain over $130 billion in cash reserves. The tech giant plans a major Siri overhaul for spring 2026, featuring enhanced conversational abilities powered by Google's Gemini technology. Recent executive changes, including Mike Rockwell taking over Siri development, signal Apple's renewed focus on AI capabilities.
12
Dec 25
Aptus Pharma Expands OTC Business in Gujarat Market
Aptus Pharma Limited is expanding its over-the-counter (OTC) business in Gujarat through its AptusWellCare Division. The expansion focuses on face care, body care, and hair care products, leveraging brands like Timglo, Kerava, and Shirovita. The company plans to enhance its product portfolio, including upcoming launches in hygiene care, pain relief, and oral care. To support this growth, Aptus Pharma is strengthening its field force and expanding its distributor network across Gujarat.
11
Dec 25
Trump Says Apple CEO Discussed Hiring Difficulties in Recent Conversation
Trump disclosed that Apple's CEO shared concerns about hiring difficulties during a recent conversation. The discussion highlighted ongoing recruitment challenges facing the technology sector. This revelation provides insight into current workforce acquisition difficulties experienced by major technology corporations.
21
Nov 25
Aptus Pharma Limited Expands into Urology Therapy Segment
Aptus Pharma Limited announces strategic expansion into the urology therapy segment. The company plans to launch multiple products, including Solifenacin Succinate Tablets for overactive bladder and Tamsulosin Hydrochloride Capsules for benign prostatic hyperplasia, subject to regulatory approvals. This move targets the growing global urology devices market, projected to reach $62.76 billion by 2028. The company aims to leverage its existing distribution network and manufacturing capabilities, while exploring partnerships to support growth in this new segment.
11
Nov 25
Aptus Pharma Limited Reports Robust 47% Revenue Growth in H1
Aptus Pharma Limited announced robust financial results for H1 FY24. Total revenue increased by 47.38% to Rs. 1,437.75 lakhs, EBITDA grew by 36.12% to Rs. 294.55 lakhs, and PAT rose by 33.81% to Rs. 174.69 lakhs compared to the previous year. The company experienced slight margin compression with EBITDA margin at 20.49% and PAT margin at 12.15%. Growth was attributed to product portfolio expansion, strengthened marketing network, and improved operational efficiency. The company plans to continue investing in new products, digital initiatives, and distribution expansion.
Aptus Pharma
330.
20
+
15.
70
(+
4.
99
%)
1 Year Returns:
+289.20%
Industry Peers
LG Electronics
1,562.00
(-
0.
95
%)
Voltas
1,414.20
(-
2.
43
%)
Blue Star
1,833.20
(-
6.
16
%)
Amber Enterprises
6,446.00
(-
6.
98
%)
Crompton Greaves
246.25
(-
0.
38
%)
V-Guard Industries
320.00
(+
0.
41
%)
Whirlpool
837.65
(-
2.
70
%)
Eureka Forbes
438.05
(-
1.
61
%)
TTK Prestige
542.00
(-
6.
28
%)
Symphony
799.10
(-
2.
01
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO